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Abstract
Purpose The human physiological bladder contraction is
largely mediated by acetylcholine acting on muscarinic
receptors, but in pathophysiological settings the relative
role of non-cholinergic stimuli gains importance. -Adre-
noceptor agonists are currently in clinical development as
treatments for the overactive bladder syndrome. Therefore,
we have explored the ability of the -adrenoceptor agonist
isoprenaline to induce rat isolated bladder strip relaxation
on pre-contraction with the muscarinic agonist carbachol as
compared to bladder tone induced by several non-choliner-
gic stimuli.
Methods Bladder tone was induced by passive tension,
receptor independently by KCl, carbachol, bradykinin or
serotonin. Concentration–response curves were generated
for relaxation by isoprenaline, and a single concentration of
the receptor-independent relaxant forskolin was also tested.
Results The various contractile stimuli induced diVerent
degrees of bladder tone, but the ability of isoprenaline or
forskolin to relax rat bladder was not correlated with the
degree of tone. Isoprenaline was signiWcantly less potent
and eVective in causing relaxation against carbachol-
induced tone than against any other stimulus, whereas no
such relationship was observed for forskolin.
Conclusions We conclude that -adrenoceptor agonists
can induce rat bladder relaxation against a wide range of
contractile stimuli and are more potent and/or eVective
against non-cholinergic stimuli than against muscarinic
agonism. This proWle appears desirable for agents intended
for the treatment of overactive bladder.
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Introduction
The physiological voiding contractions of the human urinary
bladder are primarily elicited by the parasympathetic pelvic
nerves, which release acetylcholine to act on muscarinic
receptors, mainly of the M3 subtype [1]. This is diVerent
from the situation in non-primate species, where non-cholin-
ergic agents contribute considerably to physiological void-
ing [2]. However, under pathophysiological conditions, the
relative role of non-cholinergic stimuli in mediating bladder
contraction increases also in humans [3–6]. This may at
least partly explain why muscarinic receptor antagonists
have only moderate eYcacy relative to placebo in the treat-
ment of the overactive bladder syndrome (OAB) [7, 8].
The storage function of the urinary bladder requires
smooth muscle relaxation to accommodate increasing vol-
umes of urine without major elevations of intravesical pres-
sure [9].  -Adrenoceptor stimulation provides an eVective
means to cause bladder smooth muscle relaxation, and, in
most species including humans, this involves a strong 3-
adrenoceptor component [10]. Accordingly, 3-adrenoceptor-
selective agonists are currently under clinical development for
the treatment of OAB, and clinical proof of concept data for
their eYcacy have recently been presented [11].
Treatments for OAB patients should inhibit non-voiding
bladder contractions, but have only little eVect against
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physiological voiding contractions of the bladder. The latter
is largely mediated by muscarinic receptor stimulation,
whereas the former involves non-cholinergic mechanisms
to a major degree. One previous study in rat bladder has
indicated that the -adrenoceptor agonist isoprenaline is
more potent against the receptor-independent contractile
stimulus KCl than against the muscarinic receptor agonist
carbachol [12]. While KCl is often used in experimental in
vitro studies to induce smooth muscle contraction, it is
unclear how this relates to pathophysiological non-cholin-
ergic stimuli. Therefore, we compared the ability of the
prototypical -adrenoceptor agonist isoprenaline to induce
carbachol-induced bladder contraction with that induced by
a range of other stimuli.
Materials and methods
All experiments were performed according to the German
legislation on experimental animals and with approval by
the state animal welfare board. Male adult Wistar rats were
obtained from the central animal breeding facility of the
University of Duisburg-Essen. Relaxation experiments
were performed as previously described [13] with minor
modiWcations. BrieXy, bladder strips (approximate diame-
ter 1 mm, length 20 mm, weight 10 mg) were mounted
under a resting tension of 10 mN in 10 ml organ baths con-
taining Krebs–Henseleit buVer of the following composi-
tion (mM): NaCl 119, KCl 4.7, MgSO4 1.2, Na4EDTA
0.027, CaCl2 2.5, KH2PO4 1.2, NaHCO3 25, glucose 5.5
and HEPES 10 mM at 37°C and continually gassed with
95% O2 and 5% CO2 to maintain a pH of 7.4. The bladder
strips were allowed to equilibrate for 60 min during which
the buVer was refreshed several times. Thereafter, the strips
were stimulated three times with 50 mM KCl followed by
20 min of washout. At the end of the equilibration period,
the buVer was replaced and passive tension was readjusted
at 10 mN. Where indicated, 50 mM KCl, 1 M carbachol,
100 M serotonin or 3 M bradykinin were added; this
induced an initial increase in the force of contraction,
which partly abated to reach relatively stable plateau val-
ues. Those plateau values are depicted throughout the man-
uscript and were taken as baseline (0% relaxation) for all
subsequent relaxation experiments. While it is theoretically
possible that low and high agonist concentrations use diVer-
ent signaling pathways to elicit contraction, previous stud-
ies in the bladder do not support this notion [14].
Thereafter, cumulative concentration–response curves were
generated for relaxation by isoprenaline; parallel strips not
exposed to a -adrenoceptor agonist served as time con-
trols. To avoid desensitization, only a single concentration–
response curve was generated for each bladder strip. At the
end of each experiment, 10 M forskolin was added to each
organ bath. Bradykinin, carbachol, forskolin, isoprenaline,
serotonin and all other chemicals were from Sigma
(Munich, Germany).
Concentration–response curves were analyzed by Wtting
sigmoidal curves to the pooled data. Relaxation responses
to forskolin were expressed as percentage of the muscle
tension prior to adding the -adrenergic agonist. Relaxation
responses to isoprenaline were expressed as the percentage
of the forskolin response within the same muscle strip to
control for strip-intrinsic diVerences in relaxation potential.
Data are means § SEM of n experiments. Statistical signiW-
cance of group diVerences was found by one-way ANOVA
followed by Dunnett’s multiple comparison tests. A value
of  P < 0.05 was considered to be signiWcant. All curve
Wtting and statistical calculations were performed using the
Prism program version 4.0 (Graphpad Software, San Diego,
CA, USA).
Results
In the absence of bladder-contracting stimuli, passive ten-
sion was set to 10 mN. Bladder contraction was induced
using KCl (50 mM), the muscarinic acetylcholine receptor
agonist carbachol (1 M), serotonin (100 M) or bradyki-
nin (3 M). The latter four initially induced a peak tension,
which was followed by a decline to relatively stable plateau
values over a period of approximately 20 min. Thereafter,
i.e., immediately prior to addition of isoprenaline, the force
of contraction (including passive tension) was 40.2 § 1.7,
24.0 § 1.1, 11.5 § 0.3 and 13.8 § 0.5 mN for KCl, carba-
chol, serotonin and bradykinin, respectively (n = 18–21).
Under all Wve experimental conditions, bladder tone
slightly decreased with time in the presence of the vehicle.
The maximum decrease over a time course matching that
for a concentration–response curve by isoprenaline was 13–
23% with no statistically signiWcant diVerences between
groups (Table 1).
Isoprenaline concentration-dependently reduced bladder
tension under all Wve experimental conditions (Fig. 1).
Maximum relaxation and agonist potency were signiW-
cantly lower when tested against carbachol than against all
other conditions (Table 1). The combined eVects of lower
potency and eYcacy mean that, e.g., an isoprenaline con-
centration of 100 nM caused 75 § 3 and 68 § 4% relaxa-
tion against passive tension or KCl, respectively, but only
31 § 2% relaxation against carbachol. These diVerences
are not explained by diVerent degrees of tension prior to
isoprenaline addition as neither maximum relaxation nor
agonist potency was consistently related to the amount of
tension (Fig. 2).
The relaxation by 10 M forskolin, as measured at the
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was 51 § 3, 57 § 1, 75 § 3, 65 § 2 and 70 § 2% for pas-
sive tone, KCl, carbachol, serotonin and bradykinin,
respectively (n = 18–24). Thus, forskolin-induced relaxa-
tion was stronger against carbachol, serotonin or bradykinin
compared to that against passive tension (P < 0.01 each
versus passive tension in a one-way ANOVA). Again, this
was not explained by diVerent degrees of tension prior to
adding the relaxing agents, as the extent of forskolin-
induced relaxation was not signiWcantly related to the
strength of tension (Fig. 2).
Discussion
Non-voiding contractions, i.e., detrusor overactivity, are
believed to play a central role in the pathophysiology of the
overactive bladder syndrome. While physiological voiding
contractions of the human detrusor are largely mediated by
muscarinic receptors, pathological non-voiding contrac-
tions involve non-cholinergic mechanisms to a much larger
extent [3–6]. Treatments of the overactive bladder
syndrome should suppress detrusor overactivity without
impairing voiding, and -adrenoceptor agonists are one of
the future options for such treatments currently undergoing
clinical investigation [11]. Against this background, the
Table 1 EVects of pre-contraction on bladder relaxation by isoprena-
line
All Emax eVects are expressed as the percentage of the eVect of 10 M
forskolin in a given preparation. “Emax” eVects in time control experi-
ments refer to time points matching those of the concentration–
response curves for the agonists (see Wgures). Data are means § SEM
of 6–8 experiments
* P < 0.05 versus carbachol-induced contraction in a one-way
ANOVA followed by Dunnett’s multiple comparison test
Time control Isoprenaline
Maximum relaxation pEC50 Emax
Passive tension 21 § 48 . 7 6 § 0.08* 84 § 2*
KCl 23 § 28 . 0 0 § 0.06* 80 § 1*
Carbachol 13 § 27 . 2 7 § 0.15 57 § 2
Serotonin 15 § 28 . 5 4 § 0.05* 91 § 1*
Bradykinin 16 § 38 . 6 6 § 0.10* 79 § 2*
Fig. 1 Relaxation of rat urinary bladder strips by isoprenaline in rela-
tionship to pre-contraction stimulus. Data are means § SEM of 6–8
experiments. A quantitative analysis of the data is shown in Table 1
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present study has systematically explored the role of
pre-contracting stimulus on the ability of the prototypical
-adrenoceptor agonist isoprenaline to cause bladder
smooth muscle relaxation.
The purinergic receptor agonist ATP may be one of the
most important non-cholinergic pathophysiological stimuli
to elicit bladder contraction [5]. However, purinergic stim-
uli typically elicit only phasic contractions, which do not
allow testing relaxation against tension induced by them in
our experimental design. Therefore, we chose to test a
range of other non-cholinergic stimuli, which in total
should provide a good picture of non-cholinergic contrac-
tion. As expected [9], these stimuli induced diVerent
degrees of bladder tone. However, neither the ability of the
receptor-independent stimulus forskolin nor the potency or
eYcacy of isoprenaline to relax rat bladder strips was
related to the extent of pre-contraction. These data demon-
strate that factors distinct from the strength of pre-contrac-
tion contribute to diVerences in the ability of isoprenaline to
cause bladder relaxation. Another methodological consider-
ation is that not only the detrusor, but also the urothelium
contains functional -adrenoceptors [15] and that our
experimental protocol has not systematically removed the
urothelium. However, it can be assumed that any confound-
ing eVect of the urothelium was consistent across all exper-
imental conditions.
To the best of our knowledge, only one previous study
has compared relaxation against a muscarinic agonist with
that against a non-cholinergic stimulus [12]. These authors
found isoprenaline to be a weaker relaxant against carba-
chol than against the receptor-independent stimulus KCl.
This observation was conWrmed in the present study, but it
remains unclear how relevant KCl is as a comparative stim-
ulus, because relaxation against KCl can diVer from that
against passive tension [16]. Therefore, we compared relax-
ation against carbachol with that against four other condi-
tions and found that carbachol-induced tone was more
diYcult to relax by isoprenaline than that by any other stim-
ulus. This “resistance” of carbachol-induced tone against
relaxation did not apply to the receptor-independent relaxa-
tion by forskolin. As the autonomic regulation of smooth
muscle tone in the bladder and airways has many similari-
ties [17], it is interesting to note that studies on human air-
ways has also reported that -adrenoceptor agonists cause
weaker relaxation against contraction induced by carbachol
than against other stimuli [18, 19], thus indirectly support-
ing our Wndings. One possible mechanistic explanation of
these Wndings is a speciWc interaction between M2 musca-
rinic and -adrenergic receptors as has been proposed in
rats [20] and mice [21]. This may become important if the
role of M2 receptors is enhanced under conditions of blad-
der overactivity [22]. The molecular signaling underlying
relaxation responses by -adrenoceptor agonists against
various contractile stimuli has not been investigated in
detail, but previous studies demonstrate that activation of
BKCa channels may play an important role, at least for the
relaxation against KCl-induced tone [16, 23].
In conclusion, our data show that a -adrenoceptor ago-
nist is more potent and more eYcacious in relaxing rat
bladder contraction induced by a range of non-cholinergic
stimuli as compared to that induced by the muscarinic ago-
nist carbachol. These Wndings raise the possibility that -
adrenoceptor agonists have a therapeutic window in which
they can suppress detrusor overactivity without impairing
physiological voiding. While the present rat study does not
allow conclusions on the -adrenoceptor subtype being tar-
geted, the predominant role of 3-adrenoceptors in the
human bladder [10] suggests that a drug useful in patients
should be 3-selective. While this remains to be conWrmed
in urodynamic studies in patients, it is noteworthy that
indeed the 3-adrenoceptor agonist mirabegron was
recently shown to eVectively reduce voiding dysfunction in
OAB patients without apparent interference with physio-
logical voiding [11].
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